Corpus ID: 79214873

Transvaginal administration of progesterone : the vaginal paradox and the first uterine pass effect hypothesis

@inproceedings{Ziegler1995TransvaginalAO,
  title={Transvaginal administration of progesterone : the vaginal paradox and the first uterine pass effect hypothesis},
  author={D. Ziegler and E. Sch{\"a}rer and L. Seidler and R. Fanchin and C. Bergeron},
  year={1995}
}
CME INFORMATION Examining the Evidence: Progesterone Supplementation During Fresh and Frozen Embryo Transfer
TLDR
A Summit was convened to critically review the literature on progesterone supplementation in assisted reproductive transfer cycles in general, and after FET and to provide guidance on the most clinicallyrelevant issues. Expand
Examining the evidence: progesterone supplementation during fresh and frozen embryo transfer.
TLDR
A Summit was convened to review the literature on progesterone supplementation in ART and after FET and to provide guidance on the most clinically relevant issues, and the clinically relevant topic areas were the rationale for progestersone supplementation, timing and appropriate dosing. Expand
Luteal phase support using either Crinone 8% or Utrogest: results of a prospective, randomized study.
TLDR
A prospective, randomized study investigated 126 patients undergoing cycles of in vitro fertilization and IVF/intracytoplasmic sperm injection and found that Crinone 8% had a clear advantage over Utrogest as it resulted in less vaginal discharge and fewer application difficulties. Expand
Evaluation of an optimal luteal phase support protocol in IVF
TLDR
It could be shown that h CG is as effective as is progesterone for luteal phase support but hCG is accompanied by a higher rate of complications. Expand
Prospective, randomized study to evaluate the success rates using hCG, vaginal progesterone or a combination of both for luteal phase support
TLDR
A prospective study was done to compare the efficacy of luteal phase support (LPS) using either three times hCG, hCG on the day of embryo transfer (ET) in combination with daily vaginal progesterone or vaginal progestersone only. Expand
Uterine Contractility: Vaginal Administration of the β‐Adrenergic Agonist, Terbutaline
TLDR
Results indicate that uterine targeting of terbutaline can be accomplished through vaginal administration, suggesting a new therapeutic modality in women's health care. Expand
Ovarian markers of implantation potential in assisted reproduction.
TLDR
The markers of implantation described include the expression of 11 beta-hydroxysteroid dehydrogenase by granulosa cells in vitro and perifollicular vascularity and vascular endothelial growth factors bound togranulosa and cumulus cells. Expand
Uterine contractions at the time of embryo transfer alter pregnancy rates after in-vitro fertilization.
TLDR
The results indicate that high frequency UC on the day of embryo transfer hinder IVF-embryo transfer outcome, possibly by expelling embryos out of the uterine cavity, and the negative correlation between UC frequency and progesterone concentrations supports the uterusine relaxing properties of progester one. Expand
Targeted drug delivery in gynaecology: the first uterine pass effect.
TLDR
The data demonstrate that a 'first uterine pass effect' occurs when drugs are delivered vaginally, thereby providing an explanation for the unexpectedly high uterine concentrations relative to the low serum concentration observed after vaginal administration. Expand